Boston Partners Has $260.61 Million Holdings in Sanofi (NASDAQ:SNY)

Boston Partners lifted its holdings in shares of Sanofi (NASDAQ:SNY) by 86.4% during the fourth quarter, Holdings Channel.com reports. The firm owned 5,396,531 shares of the company’s stock after acquiring an additional 2,501,073 shares during the quarter. Boston Partners’ holdings in Sanofi were worth $260,607,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of the business. Thrivent Financial for Lutherans lifted its holdings in shares of Sanofi by 36.0% during the fourth quarter. Thrivent Financial for Lutherans now owns 1,943,761 shares of the company’s stock worth $93,774,000 after purchasing an additional 514,542 shares during the period. Signaturefd LLC lifted its holdings in Sanofi by 2.3% in the fourth quarter. Signaturefd LLC now owns 38,200 shares of the company’s stock valued at $1,842,000 after buying an additional 853 shares during the period. Envestnet Portfolio Solutions Inc. lifted its holdings in Sanofi by 0.5% in the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 112,181 shares of the company’s stock valued at $5,411,000 after buying an additional 578 shares during the period. Natixis Advisors LLC lifted its holdings in Sanofi by 1.2% in the fourth quarter. Natixis Advisors LLC now owns 2,910,021 shares of the company’s stock valued at $140,350,000 after buying an additional 35,828 shares during the period. Finally, Brandes Investment Partners LP lifted its holdings in Sanofi by 3.6% in the fourth quarter. Brandes Investment Partners LP now owns 2,194,938 shares of the company’s stock valued at $105,862,000 after buying an additional 76,092 shares during the period. Institutional investors and hedge funds own 14.04% of the company’s stock.

Sanofi Price Performance

Shares of NASDAQ SNY opened at $59.11 on Wednesday. The firm’s 50-day moving average price is $54.03 and its 200-day moving average price is $52.85. Sanofi has a 1-year low of $45.22 and a 1-year high of $60.12. The firm has a market capitalization of $150.01 billion, a P/E ratio of 23.74, a P/E/G ratio of 1.01 and a beta of 0.58. The company has a current ratio of 1.46, a quick ratio of 1.14 and a debt-to-equity ratio of 0.15.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings data on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, meeting the consensus estimate of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. Equities research analysts anticipate that Sanofi will post 4.36 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently issued reports on SNY. StockNews.com lowered shares of Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Sanford C. Bernstein upgraded shares of Sanofi to a “strong-buy” rating in a report on Thursday, January 30th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “sell” rating to a “hold” rating in a report on Thursday, January 30th. Two analysts have rated the stock with a hold rating, one has given a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Sanofi currently has a consensus rating of “Buy” and a consensus price target of $60.00.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.